Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response' by Bonelli et al
| Autor: | Susan L. Fink, Andrew Bryan, Habib Rahbar, Nandita S Mani, Alison M. Bays, Anu Chaudhary, Chihiro Morishima, Mark H. Wener, Seth M. Cohen, Gregory C. Gardner, Sarah H. Chung |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Immunology Vaccine efficacy General Biochemistry Genetics and Molecular Biology Rheumatology Vaccination Immune system medicine.anatomical_structure Internal medicine medicine Immunology and Allergy Rituximab business B cell medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 80:e165-e165 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Bonelli et al recently reported reduced humoral responses to the BNT162b2 mRNA vaccine in five patients on rituximab therapy; in two patients with repopulated B cells, a low-level Spike protein antibody response occurred, but three patients with no detectable B-cells had no measurable antibody response to the vaccine.1 Of great interest, they reported that interferon-γ T-cell responses to SARS-CoV-2 Spike peptides were present in all five patients, irrespective of the antibody response to the vaccine. It has been reported that patients on B-cell depleting therapy are at increased risk for hospitalisation and death from SARS-CoV-2 infection.2 In February 2021, the American College of Rheumatology (ACR) COVID-19 Taskforce published consensus guidelines regarding vaccine timing in immunosuppressed patients, despite the paucity of data available at that time on vaccine efficacy in patients on targeted B cell therapy.3 Moreover, the guidelines specifically … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|